Asian Market Penny Stocks To Watch In July 2025

As global markets react positively to recent trade deals, with indices in the U.S. and Asia reaching new highs, investors are keenly observing the ripple effects across various sectors. Amidst this backdrop, penny stocks—often smaller or newer companies—continue to attract attention for their potential to offer unique growth opportunities. While traditionally seen as speculative, these stocks can present compelling investment cases when backed by robust financials and strategic positioning within their industries.

Top 10 Penny Stocks In Asia

Click here to see the full list of 971 stocks from our Asian Penny Stocks screener.

Let's uncover some gems from our specialized screener.

HuBei NengTer TechnologyLtd (SZSE:002102)

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: HuBei NengTer Technology Co., Ltd operates an ecommerce platform focused on the supply chain of plastic raw materials in China, with a market cap of CN¥10.59 billion.

Operations: No revenue segments have been reported for the company.

Market Cap: CN¥10.59B

HuBei NengTer Technology Ltd, with a market cap of CN¥10.59 billion, is currently pre-revenue and unprofitable. Despite this, it has a robust cash position with short-term assets exceeding both its short and long-term liabilities. The company has initiated a share buyback program worth up to CN¥50 million, which may indicate confidence in its valuation as it trades below estimated fair value. While earnings are forecasted to grow significantly at over 60% annually, the company faces challenges such as increasing debt levels and ongoing losses that have widened over the past five years.

• Click here to discover the nuances of HuBei NengTer TechnologyLtd with our detailed analytical financial health report.
• Gain insights into HuBei NengTer TechnologyLtd's outlook and expected performance with our report on the company's earnings estimates.

Tianjin Chase Sun PharmaceuticalLtd (SZSE:300026)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Tianjin Chase Sun Pharmaceutical Co., Ltd is involved in the research, development, production, and sale of various pharmaceutical products both in China and internationally, with a market cap of CN¥12.62 billion.

Operations: Revenue Segments: Not reported.

Market Cap: CN¥12.62B

Tianjin Chase Sun Pharmaceutical Ltd, with a market cap of CN¥12.62 billion, shows financial stability as its short-term assets exceed both short and long-term liabilities. The company has more cash than total debt, and its debt is well covered by operating cash flow. However, it faces challenges with declining earnings growth and reduced profit margins from 6.6% to 0.4% over the past year. Despite these setbacks, the stock trades at good relative value compared to peers and industry standards. Recent board changes may bring new strategic directions following their recent dividend affirmation for 2024 on A shares.

• Dive into the specifics of Tianjin Chase Sun PharmaceuticalLtd here with our thorough balance sheet health report.
• Explore Tianjin Chase Sun PharmaceuticalLtd's analyst forecasts in our growth report.

Hunan Er-Kang Pharmaceutical (SZSE:300267)

Simply Wall St Financial Health Rating: ★★★★☆☆

Overview: Hunan Er-Kang Pharmaceutical Co., Ltd is engaged in the manufacturing and sale of active pharmaceutical ingredients, finished drug products, and pharmaceutical excipients both in China and internationally, with a market cap of CN¥8.79 billion.

Operations: Hunan Er-Kang Pharmaceutical Co., Ltd has not reported any specific revenue segments.

Market Cap: CN¥8.79B

Hunan Er-Kang Pharmaceutical Co., Ltd, with a market cap of CN¥8.79 billion, is currently unprofitable and has seen losses increase by 25.9% annually over the past five years. The company's short-term assets of CN¥1.7 billion comfortably cover both its short-term liabilities of CN¥618.8 million and long-term liabilities of CN¥90.8 million, indicating financial stability in asset management despite profitability challenges. Its debt level is appropriate as cash holdings exceed total debt, but the stock remains highly volatile compared to other Chinese stocks, reflecting investor uncertainty amid its ongoing financial struggles and lack of significant revenue growth.

• Get an in-depth perspective on Hunan Er-Kang Pharmaceutical's performance by reading our balance sheet health report here.
• Learn about Hunan Er-Kang Pharmaceutical's historical performance here.

Where To Now?

• Unlock more gems! Our Asian Penny Stocks screener has unearthed 968 more companies for you to explore.Click here to unveil our expertly curated list of 971 Asian Penny Stocks.
• Seeking Other Investments? Explore 26 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com